In multivariable analysis of associations between initial antibiotic therapy and clinical outcomes in 5005 patients with microbiologically confirmed Streptococcus pneumoniae infections, "discordant" empiric antibiotic therapy was not associated with 30-day mortality rate (hazard ratio, 0.94; 95% confidence interval, .67-1.32).
Streptococcus pneumoniae is a leading bacterial cause of community-acquired pneumonia (CAP) among adults. It was first recognized as a cause of CAP in the preantibiotic era and was associated with severe illness and mortality rates ranging between 20% and 55% [1] . Management of patients with CAP has since evolved, with timely delivery of appropriate antibiotics being the cornerstone of therapy.
Observational data suggest that the administration of antibiotics for CAP within 4 hours in the emergency department significantly improves survival [2] . However, focusing on time to therapy as a performance measure leads to overdiagnosis and potential inappropriate antibiotic use. Current guidelines thus recommend initiation of antibiotic coverage for patients with CAP before leaving the emergency department, but no longer specify a window of time for antibiotic initiation [3] .
Recommendations for antibiotic selection vary by location and professional society. In North America, broad-spectrum cephalosporins and/or respiratory fluoroquinolones are often prescribed owing to concerns about S. pneumoniae resistance to narrower-spectrum agents. However, for patients who are not immunosuppressed or critically ill, narrower-spectrum agents can safely be used empirically; such is the standard of care in Australia and elsewhere, where guidelines recommend using intravenous penicillin with either doxycycline or a macrolide for hospitalized patients with CAP who are risk stratified and do not have evidence of severe disease [4] . The purpose of our study was to evaluate the factors related to 30-day mortality rates in patients with microbiologically proven pneumococcal pneumonia, with emphasis on the role of early appropriate antibiotic therapy.
METHODS
The Toronto Invasive Bacterial Disease Network (TIBDN) has been prospectively collecting data on invasive infections due to S. pneumoniae since 1995. Data were obtained from 25 hospital-based microbiology laboratories in the metropolitan Toronto and Peel regions (Ontario, Canada; catchment area, 4.5 million). The TIBDN collects information regarding patient demographics, comorbid conditions, antibiotic therapies, and laboratory data, as well as clinical course and outcome. Annual audits are conducted in each laboratory to ensure complete reporting. Surveillance and associated studies are approved by the research ethics boards of all participating institutions. All isolates have susceptibility testing performed by broth microdilution testing at the central study laboratory to Clinical and Laboratory Standards Institute (CLSI) standards [5] ; for this analysis, because the break points for S. pneumoniae were revised in 2008, susceptibility was determined using the current CLSI break points for nonmeningeal pneumococcal infections [6] .
Our study population comprised all individuals 18 years of age and older who were admitted to hospital from 1 January 1997 to 30 December 2014 with either bacteremia or nonbacteremic pneumococcal pneumonia, defined according to modified Musher criteria, including symptoms, clinical diagnosis, chest radiographic appearance, and sputum/bronchoscopic results positive only for S. pneumoniae [7] . Subjects were excluded if antibiotic therapy was initiated before their hospital visit or if key information regarding mortality outcome, antimicrobial susceptibility, and antibiotic administration could not be reliably obtained.
To study the effect of appropriate antibiotic selection in CAP due to S. pneumoniae, we grouped patients into those who received concordant antibiotic therapy within 1 day of admission, those who received discordant therapy during this period, and those who did not receive any therapy. Concordant antibiotic therapy was defined as the administration of an antimicrobial regimen to which the patient's isolate was susceptible. Discordant therapy represented cases in which the patients' isolates were nonsusceptible to the antimicrobial agent (intermediately susceptible or resistant). The predefined primary end point was in-hospital death within 30 days of admission.
From a review of the literature, we identified 25 potential confounders that could be abstracted from the TIDBN pneumococcal database. All variables were identified by the initial chart review based on discharge coding and physician diagnosis. Hematologic malignancy was a composite variable comprising acute leukemia, chronic leukemia, lymphoma, and myeloma.
We used the Cox proportional hazards model to assess the relationship between clinical variables and death within 30 days. All variables meeting a threshold of P < .20 in univariate analyses (not shown) were selected for evaluation in the multivariable Cox proportional hazards model. The most parsimonious model was then selected by backward selection with the forced inclusion of antibiotics. Time-dependent interaction terms were used to assess for violation of the proportional hazards assumption. To account for advances in general medical care over the 17-year period, calendar year was also included. All analyses were conducted using SAS software (version 9.3; SAS Institute).
RESULTS
A total of 6611 patients met the initial inclusion criteria for this study, of whom 5005 (75.7%) did not receive antibiotics before presentation. Their demographic, clinical, laboratory, and outcome data are shown in Table 1 . Overall, 4395 patients received antibiotics within the first day of admission, of whom 4211 (95.8%) received concordant antibiotic therapy based on final susceptibility testing. Antimicrobial nonsusceptibility ranged from approximately 1.5% for the respiratory fluoroquinolones up to 20% for macrolides (Supplementary Table S1 ). Respiratory fluoroquinolones were the most commonly prescribed antibiotic (29.0%), followed by the combination of a cephalosporin and a macrolide (15.7%), but there was significant heterogeneity in the initial choice of antibiotics. Table S2 ). After adjustment for these factors, and for year of presentation, the hazard ratio for in-patient death within 30 days was 0.94 (95% confidence interval, .67-1.32) in patients receiving discordant empiric antibiotic therapy within the first calendar day after admission (Supplementary  Table S2 ). Using the Fisher exact test, a post hoc power calculation revealed that our study had 84% power to detect an absolute difference in mortality rate of 8%, which was not observed (Supplementary Table S3 ).
DISCUSSION
We describe the results of an observational study that prospectively collected data over a 17-year period in patients who presented to the hospital with infections caused by S. pneumoniae. After adjusting for confounders, including bacteremia, medical comorbid conditions, and severity of illness (intensive care unit admission), we did not observe a significant difference in 30-day mortality rate among patients with pneumococcal pneumonia who received concordant antibiotic therapy within the first day of hospitalization versus those who did not. Given that CAP is the most common infectious syndrome requiring hospitalization in the United States [8] , a change in practice toward narrow-spectrum empiric therapy would carry significant benefits for antimicrobial stewardship. For example, penicillin could be considered as part of an empiric regimen in patients presenting to the emergency department with a diagnosis of CAP. Compared with the respiratory fluoroquinolones and third-generation cephalosporins, it offers important benefits with regard to its narrow spectrum of activity. It also offers theoretical pharmacokinetic and phamacodynamic advantages. According to surveillance data from the European Committee on Antimicrobial Susceptibility Testing, the median wild-type S. pneumoniae minimum inhibitory concentration for penicillin is 0.016 mg/L [9] ; when administered intravenously at therapeutic doses, penicillin levels would be expected to be above the minimum inhibitory concentration for an average isolate 100% of the time [10] . If prescribed with a macrolide or doxycycline, this combination would also provide coverage against most Haemophilus influenzae, Moraxella catarrhalis, and atypical organisms, without providing unnecessary Enterobacteriaceae coverage or increasing the risk of Clostridium difficile infection [11] .
Our study has several limitations. First, this is a retrospective analysis of prospectively collected data, which carries several inherent biases. These include confounding by indication, residual confounding, and misclassification bias. Second, our time resolution was limited to calendar days, and our failure to detect a difference may be due to unmeasured differences between groups in terms of exact time to antibiotic administration. Finally, although our study included >5000 patients, it may remain underpowered to detect a difference between groups, given that most patients received concordant initial therapy. Nonetheless, a post hoc power calculation suggests that we were adequately powered to detect a difference of ≥8% between groups, which was not seen (Supplementary Table  S3 ). Furthermore, our results must be interpreted in our local epidemiologic context, where we have a very low rate of S. pneumoniae nonsusceptibility to intravenous penicillin (Supplementary  Table S1 ). Nonetheless, we believe our data suggest that the majority of patients with CAP in areas of North America with low levels of penicillin nonsusceptibility could receive empiric antimicrobial therapy with intravenous penicillin, as they do in other parts of the world.
In conclusion, in this large study of admitted patients with proven pneumococcal infection, after adjusting for bacteremia and other important factors, we were unable to demonstrate a significant difference in 30-day in-hospital mortality rates between those who did and those who did not receive concordant antibiotic therapy during the first day of hospitalization. This finding may help future clinical guidelines support narrow-spectrum empiric therapy in clinically stable patients with probable pneumococcal infection or, at the least, provide enough equipoise to support a North American randomized controlled trial comparing intravenous penicillin with either doxycycline or a macrolide versus the currently recommended regimens in hospitalized patients with CAP.
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